Outpatient Treatment of Hepatitis in the Clinic
Chronic Hepatitis B
For chronic hepatitis B, initiate oral nucleoside/nucleotide analogue therapy with either entecavir or tenofovir (disoproxil fumarate or alafenamide) as first-line monotherapy 1, 2, 3.
Treatment Indications
Start antiviral therapy when:
- HBV DNA ≥2,000 IU/mL with elevated ALT (>ULN) and/or significant fibrosis 2, 3
- Any detectable HBV DNA in patients with cirrhosis, regardless of ALT level 1, 2, 3
- Detectable HBV DNA with advanced fibrosis (>F3 or liver stiffness >8 kPa), regardless of ALT 3
Specific Drug Regimens
- Entecavir: Preferred oral agent with high genetic barrier to resistance 1, 2
- Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): Alternative first-line options with high barrier to resistance 1, 2
- Peginterferon-alfa: Can be considered only in compensated patients with preserved liver function for 48 weeks, but contraindicated in decompensated cirrhosis 1
Key Monitoring Points
- Liver function tests every 2-6 months for compensated cirrhosis 1
- HBV DNA by real-time PCR every 2-6 months 1
- Treatment is typically indefinite for cirrhotic patients 1, 4
- For non-cirrhotic patients, consider stopping only after HBsAg loss (ideal endpoint) or HBeAg seroconversion with 12 months consolidation therapy plus undetectable HBV DNA 4, 2
Chronic Hepatitis C
For chronic hepatitis C, use direct-acting antiviral (DAA) combination therapy based on genotype, with sofosbuvir-based regimens as the backbone 5, 6, 7.
Genotype-Specific Regimens
Genotype 1,4,5,6:
- Sofosbuvir/ledipasvir for 12 weeks (8 weeks if treatment-naïve without cirrhosis) 6, 7
- Sofosbuvir/velpatasvir for 12 weeks 6, 7
- Glecaprevir/pibrentasvir for 8-12 weeks 7
Genotype 2:
Genotype 3:
- Sofosbuvir/daclatasvir for 12 weeks (without cirrhosis); extend to 24 weeks ± ribavirin for cirrhosis 8, 6
- Sofosbuvir/velpatasvir for 12 weeks 6
- Sofosbuvir + weight-based ribavirin (1,000-1,200 mg) for 24 weeks 8
Treatment Duration Adjustments
- Compensated cirrhosis: Generally extend to 12-24 weeks depending on regimen 8, 7
- Treatment-experienced patients: May require extended duration or addition of ribavirin 8, 7
Monitoring
- HCV RNA at baseline, week 4, week 12, end of treatment, and 12-24 weeks post-treatment for SVR assessment 5, 9
- ALT levels at same intervals 9
Acute Viral Hepatitis (A, E, and Acute Hepatitis B)
Acute viral hepatitis A and E require supportive care only; antiviral therapy is NOT routinely indicated 10, 11.
Supportive Management
- Bedrest if symptomatic 10
- High-calorie diet 10
- Avoid hepatotoxic medications (including acetaminophen) and alcohol 5, 10
- Intravenous rehydration if unable to maintain oral intake 10
Acute Hepatitis B
Antiviral therapy should be considered ONLY in cases of persistent severe hepatitis or acute liver failure 12.
- Use oral nucleoside analogues (lamivudine historically studied, but entecavir or tenofovir preferred based on current standards) 12
- Monitor for spontaneous resolution in most cases, as >95% of adults clear acute HBV infection without treatment 12
- Early antiviral therapy may interfere with protective immune response 12
Acute Hepatitis C
For recently acquired hepatitis C, treat with sofosbuvir-based DAA regimens for 8-12 weeks 6, 7.
- Sofosbuvir/ledipasvir for 8 weeks (genotypes 1,4,5,6) 6
- Sofosbuvir/velpatasvir for 8 weeks (all genotypes) 6
- Sofosbuvir/daclatasvir for 8 weeks (all genotypes) 6
- Consider extending to 12 weeks if HIV coinfection or baseline HCV RNA >1 million IU/mL 6
- Monitor for at least 12-16 weeks before initiating treatment to allow for spontaneous clearance 5
Critical Pitfall
Do NOT delay treatment in acute hepatitis C beyond 6 months if spontaneous clearance has not occurred, as this increases transmission risk and progression to chronicity 7. The historical practice of waiting 6 months is outdated with current DAA availability 7.